Extract

To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from baseline (from trial 156-04-251) in total kidney volume (TKV) and renal function.

Inclusion criteria

• Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Country

• Argentina
• Australia
• Belgium
• Canada
• France
• Germany
• Italy
• Netherlands
• Poland
• Romania
• Russian Federation
• United Kingdom
• United States

Links

• nct
• ictrp